A

Agios Pharmaceuticals
D

AGIO

40.040
USD
-0.34
(-0.84%)
مغلق
حجم التداول
22,510
الربح لكل سهم
-7
العائد الربحي
-
P/E
3
حجم السوق
2,318,924,568
أصول ذات صلة
C
CRSP
10.120
(18.39%)
65.140 USD
E
EDIT
0.03500
(1.28%)
2.76000 USD
N
NTLA
0.225
(1.90%)
12.050 USD
Q
QURE
-0.175
(-1.15%)
15.015 USD
R
RARE
-1.090
(-3.98%)
26.320 USD
S
SGMO
0.01430
(2.93%)
0.50190 USD
S
SRPT
-7.925
(-36.02%)
14.075 USD
المزيد
الأخبار المقالات

العنوان: Agios Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.